Compare Ascendis Pharma A/S (ASND) vs Bandwidth Inc (BAND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Bandwidth Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Bandwidth Inc trades at $76 (market cap $2.42B). The key difference: Ascendis Pharma A/S is far larger — about 7.3× Bandwidth Inc's market cap. Which is the better fit depends on your goals.
| ASND | BAND | |
|---|---|---|
Market Cap | $17.74B | $2.42B |
Sector | Health | Technology |
52-Week High | $277.18 | $78.44 |
52-Week Low | $163.32 | $12.82 |
Enterprise Value | $18.11B | $2.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Bandwidth (BAND) trades at $75.48, down 3.77% on the day, with strong technical momentum despite recent weakness. The stock shows bullish technical signals with 19 buy indicators versus 6 sell, while fundamentals reveal mixed performance with negative net income margins (-0.64%) but solid revenue growth to $753.82 million in 2025. Recent news highlights AI platform expansion and a $275 million convertible notes offering to fuel growth initiatives.
Outlook remains cautiously optimistic with 75% analyst buy ratings and an $85 high price target, though profitability challenges and elevated valuation metrics (EV/EBITDA 63.18) present risks. The upcoming Q2 2026 earnings report on July 29 will be crucial for validating the AI-driven growth narrative.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Bandwidth Inc
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →
